NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
3.290
+0.110 (3.46%)
Nov 20, 2024, 4:00 PM EST - Market closed
NLS Pharmaceutics AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 4.52 | 5.9 | 6.51 | 5.94 | 2.2 | 3.3 | |
| Research & Development | 1.8 | 5.91 | 8.98 | 5.92 | 0.1 | 0.9 | |
| Operating Expenses | 6.31 | 11.81 | 15.48 | 11.86 | 2.3 | 4.2 | |
| Operating Income | -6.31 | -11.81 | -15.48 | -11.86 | -2.3 | -4.2 | |
| Interest Expense | -0.23 | -0.15 | -0.1 | -0.07 | -0.23 | -0.82 | |
| Other Non Operating Income (Expenses) | -0.05 | -0.22 | 0.01 | -0.02 | -0.33 | -0.07 | |
| EBT Excluding Unusual Items | -6.6 | -12.17 | -15.57 | -11.95 | -2.86 | -5.08 | |
| Other Unusual Items | - | - | -0.92 | - | - | -0.36 | |
| Pretax Income | -6.6 | -12.17 | -16.5 | -11.95 | -2.86 | -5.45 | |
| Net Income | -6.6 | -12.17 | -16.5 | -11.95 | -2.86 | -5.45 | |
| Net Income to Common | -6.6 | -12.17 | -16.5 | -11.95 | -2.86 | -5.45 | |
| Shares Outstanding (Basic) | 1 | 1 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 1 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 29.96% | 93.96% | 65.38% | 71.00% | 1.75% | 9.62% | |
| EPS (Basic) | -6.59 | -12.75 | -33.52 | -40.15 | -16.45 | -31.85 | |
| EPS (Diluted) | -6.59 | -12.75 | -33.52 | -40.15 | -16.45 | -31.85 | |
| Free Cash Flow | -3.92 | -9.68 | -13.88 | -14.98 | -0.73 | -0.19 | |
| Free Cash Flow Per Share | -3.91 | -10.15 | -28.21 | -50.33 | -4.19 | -1.11 | |
| EBITDA | -6.3 | -11.8 | -15.47 | -11.85 | - | - | |
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | - | - | |
| EBIT | -6.31 | -11.81 | -15.48 | -11.86 | -2.3 | -4.2 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.